For investors, the debate is shifting: From: Can India manufacture complex GLP1s at global quality? To: How fast can Indian CDMOs, led by Divis, scale throughput to match the GLP1 demand curve? In portfolio terms: Divis Labs screens as the highest-operating-leverage, highest-conviction GLP1 manufacturing proxy, albeit with elevated execution and valuation risk
Ishan Rastogi Address S-8, Surya Apartments 1, Behind Raymond Showroom, Sector 104, Gautam Budh Nagar, Noida, Uttar Pradesh, 201304, India pharmaceutical injection in Noida Report incorrect details
Clin Pharmacokinet 2012;51:553-72
As of early 2025 data, 11 states covered GLP-1 medications for weight loss under their state employee health plans
This broad receptor activity has made Melanotan 2 acetate a versatile tool for investigating diverse melanocortin-mediated pathways in laboratory settings